UNSPSC 51162030: Fluticasone/salmeterol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162030 Fluticasone/salmeterol is a Commodity code, but the recent state and local procurement activity tagged under it does not align with this specific pharmaceutical product. Instead, opportunities solicited under this code span naloxone procurement, on-site pharmacy services provision, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — a scope substantially broader than a single branded respiratory combination therapy. The mismatch suggests either tagging inconsistency in the source data or a code assignment that reflects higher-tier pharmaceutical procurement categories rather than this specific drug formulation. State and local buyers posting under this code include county health departments and community health programs (Seminole County, Florida), county government employees and retirees (Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and multi-jurisdictional cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon).

Recent opportunities show geographic spread across Florida, Georgia, Texas, and Minnesota, with a multi-state cooperative structure adding reach beyond individual state boundaries. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery (due July 26, 2023), Hall County's RFQ/P for on-site pharmacy services at a county health center serving approximately 3,005 eligible individuals across multiple insurance plans (due June 4, 2026), Texas HHS's RFI exploring direct-to-manufacturer prescription capabilities (April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with proposals due March 26, 2026. The cooperative purchasing model and multi-award structures suggest that state and local buyers are consolidating pharmaceutical procurement through wholesaler-authorized channels rather than contracting directly with individual manufacturers, with pricing and cost competitiveness heavily weighted in evaluations across most opportunities.